Marshall Wace
NKGN

Marshall Wace’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Marshall Wace’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-589,724
Closed -$5.87M – 3208
2022
Q4 		$5.87M Hold
589,724
– – 0.01% 1098
2022
Q3 		$5.75M Buy
589,724
+535,635
+990% +$5.23M 0.01% 1273
2022
Q2 		$525K Hold
54,089
– – ﹤0.01% 2769
2022
Q1 		$523K Hold
54,089
– – ﹤0.01% 2754
2021
Q4 		$523K Buy
54,089
+3,552
+7% +$34.6K ﹤0.01% 2772
2021
Q3 		$490K Buy
+50,537
New +$493K ﹤0.01% 2392

Other funds holding NKGN

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

Marshall Wace's NKGN Position: Q1 2023 in Review

Marshall Wace sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q1 2023, closing a stake of 589,724 shares — an estimated $5.87M sold.

Marshall Wace first reported a position in NKGN in Q3 2021 and held it in 6 quarters. The position peaked at $5.87M in Q4 2022. 55 funds tracked by Wall St. Rank hold NKGN as of Q1 2023.

  • Marshall Wace reported no remaining NKGen Biotech, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Marshall Wace sold 589,724 NKGen Biotech, Inc. Common Stock shares in Q1 2023, an estimated $5.87M.
  • Marshall Wace first reported a position in NKGen Biotech, Inc. Common Stock in Q3 2021 and held it in 6 quarters.
  • Marshall Wace's NKGen Biotech, Inc. Common Stock position peaked at $5.87M in Q4 2022.
  • 55 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q1 2023.

Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.